A comprehensive analysis of CBER experience with AAV gene therapy IND submissions

Sojin Bing, Takele Argaw, Megha Kaushal, Ronit Mazor
Nature Biotechnology · Springer Nature · 2026-11-12 · DOI: 10.1038/s41587-026-03378-9

Аннотация

Nature Biotechnology, Published online: 12 November 2026; doi:10.1038/s41587-026-03378-9 An analysis of Investigational New Drug (IND) submissions to the US Food and Drug Administration (FDA) from 1995 to 2025 reveals a rapid growth in adeno-associated virus (AAV) development over three decades and highlights common reasons for regulatory holds that should be considered for successful product development.

Читать у издателя →

Похожие статьи